• Inicio
  • Formações
  • Formação à Medida
  • News & Trends
  • Sobre nós
  • Contacto

Data Integrity and Compliance With Drug CGMP

FDA expects that all data be reliable and accurate (see the “Background” section). CGMP regulations and guidance allow for flexible and risk-based strategies to prevent and detect data integrity issues. Firms should implement  meaningful and effective strategies to manage their data integrity risks based on their process understanding and knowledge management of technologies and business models.

Data Integrity and Compliance With Drug CGMP .Questions and Answers Guidance for Industry

News & Trends

Procurar

Recentes

  • EU CTR Q&A Version 7.3 is Out
  • New WHO guide on Artificial intelligence-related health research
  • GDP for APIs: APIC Publishes Updated “How to Do” Document
  • Team-NB Position Paper :TRANSFER AGREEMENT FOR SURVEILLANCE OF LEGACY DEVICES
  • MDR Certification Process (including Pre-application, Application and Post Application phases) – Consensus document
  • New ISO Guidance for AI-Powered Medical Devices: ISO/TS 24971-2:2026 Published!
  • Commission publishes guidelines on transparency obligations for providers and deployers of certain AI systems
  • MDCG Position Paper: UDI assignment between manufacturers and distributors

91 257 00 03 (Chamada para a rede móvel nacional)
info@formiventos.com

  • Follow
  • CLIENTES & TESTIMONIALS
  • ASSOCIAÇÕES OFICIAIS
  • CERTIFICAÇÕES E CREDITAÇÕES
  • ADVISORY BOARD
  • Política de Privacidade
  • Contacto